Nonsurgical repigmentation therapies in vitiligo: Meta-analysis of the literature

Archives of Dermatology

Volumn 134, Issue 12, 1998, Pages 1532-1540

  Njoo, M D ^a,b   Spuls, P I ^a   Bos, J D ^a   Westerhof, W ^a   Bossuyt, P M M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BERGAPTEN; BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; CORTICOSTEROID; HALOMETASONE; KHELLIN; METHOXSALEN; PSORALEN; TRIAMCINOLONE ACETONIDE; TRIOXYSALEN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG INDUCED DISEASE; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; ORAL DRUG ADMINISTRATION; PHOTOCHEMOTHERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PRURITUS; PUVA; RANDOMIZED CONTROLLED TRIAL; SKIN ATROPHY; SKIN DISEASE; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VITILIGO; VOMITING;

HUMANS; RANDOMIZED CONTROLLED TRIALS; VITILIGO;

EID: 0032429810     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.134.12.1532     Document Type: Article

References (58)

1. Srivastava G. Introduction: vitiligo update. Asian Clin Dermatol. 1994;1:1-4.
2. Porter J, Beuf AH, Lerner AB, Nordlund JJ. Response to cosmetic disfigurement: patients with vitiligo. Cutis. 1987;39:493-494.
3. Ortonne JP. Psoralen therapy in vitiligo. Clin Dermatol. 1989;7:120-135.
4. Antoniou C, Katsambas A. Guidelines for the treatment of vitiligo. Drugs. 1992; 43:490-498.
5. Nordlund JJ, Halder RM, Grimes PE. Management of vitiligo. Dermatol Clin. 1993; 11:27-33.
6. Grimes PE. Vitiligo: an overview of therapeutic approaches. Dermatol Clin. 1993; 11:325-338.
7. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for vitiligo. J Am Acad Dermatol. 1996;35:620-626.
8. Westerhof W, Njoo MD, Schallreuter KU. Vitiligo: Weiterbildung. Hautarzt. 1997; 48:677-693.
9. Huth EJ. Needed: review articles with more scientific rigor. Ann Intern Med. 1987; 106:470-471.
10. Mulrow CD. The medical review article: state of the science. Ann Intern Med. 1987; 104:485-488.
11. Antman EM, Lau J, Kupelnick B. A comparison of results of meta-analysis of randomized controlled trials and recommendations of clinical experts. JAMA. 1992; 268:240-248.
12. Oxman AD, Guyatt GH. The science of reviewing research. Ann N Y Acad Sci. 1993;703:125-134.
13. Evidence-Based Medicine Working Group. Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA. 1992;268:2420-2425.
14. Sackett DL, Rosenberg WM, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-72.
15. Ladhani S. The need for evidence-based management of skin diseases. Int J Dermatol. 1997;36:17-22.
16. Mulrow CD. Rationale for systematic reviews. BMJ. 1994;309:597-599.
17. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309:1286-1291.
18. Eddy DM. Practice policies: what are they? JAMA. 1990;263:877-880.
19. Cook DJ, Greengold NL, Ellrodt AG, Weingarten SR. The relation between systematic review and practice guidelines. Ann Intern Med. 1997;127:210-216.
20. Altman DG. Comparing groups; categorical data. In: Altman DG, ed. Practical Statistics for Medical Research. London, England: Chapman & Hall; 1997:268-271.
21. DerSimonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177-188.
22. Koopmans-van Dorp B, Goedhart-van Dijk B, Neering H, van Dijk E. Treatment of vitiligo by local application of betamethasone 17-valerate in a dimethyl sulfoxide cream base. Dermatologica. 1973;146:310-314.
23. Kandil E. Treatment of vitiligo with 0-1% betamethasone 17-valerate in isopropyl alcohol: a double-blind trial. Br J Dermatol. 1974;91:457-460.
24. Bleehen SS. The treatment of vitiligo with topical corticosteroids: light and electron microscopic studies. Br J Dermatol. 1976;94(suppl 12):43-50.
25. Clayton R. A double-blind trial of 0.05% clobetasol proprionate in the treatment of vitiligo. Br J Dermatol. 1977;96:71-73.
26. Vasistha LK, Singh G. Vitiligo and intralesional steroids. Indian J Med Res. 1979; 69:308-311.
27. Orecchia G, Perfetti L. Photochemotherapy with topical khellin and sunlight in vitiligo. Dermatology. 1992;184:120-123.
28. Procaccini EM, Riccio G, Monfrecola G. Ineffectiveness of topical khellin in photochemotherapy of vitiligo. J Dermatol Treatment. 1995;6:117-120.
29. Procaccini EM, Riccio G, Viola L, Monfrecola G. Evaluation of topical khellin photochemotherapy for vitiligo. Ann Ital Dermatol Clin Sperimentale. 1993;47: 275-278.
30. Koga M. Vitiligo: a new classification and therapy. Br J Dermatol. 1977;97:255-261.
31. Pathak MA, Mosher DB, Fitzpatrick TB. Safety and therapeutic effectiveness of 8-methoxypsoralen, 4,5,8-trimethylpsoralen, and psoralen in vitiligo. Natl Cancer Inst Monogr. 1984;66:165-173.
32. Ruiz Maldonado R, Tamayo Sanchez L. 4-5-8 Trimethylpsoralen in vitiligo: controlled clinical study of its therapeutic and toxic effect in children. Actas Dermosifiliograficas. 1975;66:513-526.
33. Farah FS, Kurban AK, Chaglassian HT. The treatment of vitiligo with psoralens and triamcinolone by mouth. Br J Dermatol. 1967;79:89-91.
34. Antoniou C, Schulpis H, Michas T, et al. Vitiligo therapy with oral and topical phenylalanine with UVA exposure. Int J Dermatol. 1989;28:545-547.
35. Orecchia G, Perfetti L. Photochemotherapy with topical khellin and sunlight in vitiligo. Dermatology. 1992;184:120-123.
36. Siddiqui AH, Stolk LM, Bnaggoe R, Hu R, Schutgens RB, Westerhof W. L-phenylalanine and UVA irradiation in the treatment of vitiligo. Dermatology. 1994; 188:215-218.
37. Al-Khawajah MM. The failure of L-phenylalanine and UVA in the treatment of vitiligo. J Dermatol Treatment. 1996;7:181-182.
38. Abdel-Fattah A, Aboul-Enein MN, Wassel GM, El-Menshawi BS. An approach to the treatment of vitiligo by khellin. Dermatologica. 1982;165:136-140.
39. Petzoldt D, Reich AL. Oral treatment of vitiligo with 8-methoxypsoralen and triamcinolone. Hautarzt. 1974;25:191-194.
40. El Zawahry M, Soliman M, El Ansary M, El Zawahry MB, Mahdy Rady EAA. A clinical and immunological study of the effect of the different modalities of treatment on vitiligo patients. J Pan Arab League Dermatol. 1997;8:63-75.
41. Drake LA, Ceilly RI, Dorner W, et al. Guidelines of care for phototherapy and photochemotherapy. J Am Acad Dermatol. 1994;31:643-648.
42. Easterbrook PJ, Berling JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867-872.
43. Kanthraj GR. Comparison of computer-aided design and rule of nines methods in the evaluation of the extent of body involvement in cutaneous lesions. Arch Dermatol. 1997;133:922-923.
44. Elliott JA, Charlotte NC. Methoxsalen in the treatment of vitiligo: an appraisal of the permanency of the repigmentation. Arch Dermatol. 1958;79:237-243.
45. Kenney JA Jr. Vitiligo treated by psoralens: a long-term follow-up study of the permanency of repigmentation. Arch Dermatol. 1971;103:475-480.
46. Theodoridis A, Tsambaos D, Sivenas C, Capetanakis J. Oral trimethylpsoralen in the treatment of vitiligo. Acta Derm Venereol. 1976;56:253-256.
47. Köster W, Wiskemann A. Phototherapy with UV-B in vitiligo. Z Hautkr. 1990;65: 1022-1024.
48. Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UVB (311 nm) versus topical PUVA. Arch Dermatol. 1997;133:1525-1528.
49. Slaper H, Schothorst AA, van der Leun JC. Risk evaluation of UVB therapy for psoriasis: comparison of calculated risk for UVB therapy and observed risk in PUVA treated patients. Photodermatology. 1986;3:271-283.
50. Sterenborg HJCM, van Weelden H, van der Leun JC. The dose-response relationship for tumorigenesis by UV radiation in the region 311-312 nm. J Photochem Photobiol B. 1988;2:179-194.
51. Young AR. Photocarcinogenicity of psoralens used in PUVA treatment: present status in mouse and man. J Photochem Photobiol B. 1990;6:237-247.
52. Stern RS, Lange R, members of the Photochemotherapy Follow-up Study. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol. 1988;91:120-124.
53. Buckley DA, Rogers S. Multiple keratoses and squamous carcinoma after PUVA treatment of vitiligo. Clin Exp Dermatol. 1996;21:43-45.
54. Takeda H, Mitsuhashi Y, Kondo S. Multiple squamous cell carcinomas in situ in vitiligo after long-term PUVA therapy. J Am Acad Dermatol. 1998;38: 268-270.
55. British Photodermatology Group. British Photodermatology Group guidelines for PUVA. Br J Dermatol. 1994;130:246-255.
56. Imamura S, Tagami H. Treatment of vitiligo with oral corticosteroids. Dermatologica. 1976;153:179-185.
57. Pasricha JS, Khaitan BK. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol. 1993;32: 753-757.
58. Moon TK, Im SB, Hann SK, Cho SH, Park YK. The effect of small doses of oral corticosteroids in vitiligo patients. Korean J Dermatol. 1995;33:880-885.